1 (Image 1)
Chemical structure diagram of lisdexamfetamine dimesylate, showing the arrangement of atoms and bonds in the active pharmaceutical ingredient.*
Lisdexamfetamine Dimesylate Capsule
Product Images NDC 0480-3567
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 0480-3567). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
1 (Image 10)
Label for Lisdexamfetamine Dimesylate Capsules 10 mg, oral capsules supplied in a bottle of 100 capsules. The label includes storage instructions, metabolism information, and manufacturer details for Teva Pharmaceuticals, Inc. The NDC is 0480-3565-01.*
1 (Image 11)
Lisdexamfetamine dimesylate 20 mg capsules packaging label from Teva Pharmaceuticals, Inc. The label includes dosage strength (20 mg), quantity (100 capsules), and directs pharmacists to dispense the medication guide. It features the NDC number 0480-3566-01 and storage instructions. The label is primarily white with green and pink accents.*
1 (Image 12)
Label for Lisdexamfetamine Dimesylate Capsules, 30 mg by Teva Pharmaceuticals, Inc. The label includes NDC 0480-3567-01 and states the package contains 100 capsules for Rx only. It provides medication guide instructions, storage conditions, and manufacturer information.*
1 (Image 13)
Label for Lisdexamfetamine Dimesylate Capsules 40 mg by Teva Pharmaceuticals, Inc. The label indicates the product is for oral use, contains 100 capsules, and includes usage and storage information. The Teva logo appears on the label alongside dosage and handling guidelines.*
1 (Image 14)
Lisdexamfetamine Dimesylate Capsules 50 mg oral capsules, packaged in a label showing 100 capsules. The label includes the NDC 0480-3569-01 and states the product is manufactured by Teva Pharmaceuticals, Inc. It advises dispensing the accompanying Medication Guide and includes storage and dosage instructions.*
1 (Image 15)
Lisdexamfetamine Dimesylate Capsules 60 mg oral capsule label from Teva Pharmaceuticals, Inc. The label includes dosage strength, package quantity of 100 capsules, instructions to dispense the accompanying medication guide, storage conditions, and manufacturer information. Barcode and serialization coding area are also visible.*
1 (Image 16)
Lisdexamfetamine dimesylate Capsules 70 mg label from Teva Pharmaceuticals, Inc. The label includes medication guidance instructions, states the packaging contains 100 capsules, and provides storage information along with a barcode and serialization coding area.*
1 (Image 2)
A chart showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of lisdexamfetamine dimesylate in special populations categorized by gender, age groups (65-74 years, 75+ years), and renal impairment severity (mild, moderate, severe, end stage renal disease). The horizontal axis represents the change relative to reference from 0.0 to 2.5.*
1 (Image 3)
A forest plot chart depicting pharmacokinetic fold changes and 90% confidence intervals for Cmax and AUC parameters of Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents change relative to a reference, ranging from 0 to 2. Each drug's data points with error bars show how their pharmacokinetic measures compare to the reference.*
1 (Image 4)
A forest plot chart depicting fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of various interacting drugs relative to a reference. The drugs include Guanfacine, Venlafaxine, CYP1A2 substrates (Caffeine), CYP2D6 substrates (Dextromethorphan), CYP2C19 substrates (Omeprazole), and CYP3A substrates (Midazolam). The x-axis shows change relative to reference from 0.0 to 2.0.*
1 (Image 5)
A line graph comparing LS Mean (SE) SKAMP Deportment Scores over time post-dose between Lisdexamfetamine Dimesylate Capsules and placebo groups. The x-axis shows time in hours post-dose, ranging from 0 to 13 hours. The y-axis shows SKAMP Deportment Scores from 0.1 to 2.0. The graph displays a solid line for Lisdexamfetamine dimesylate and a dashed line for placebo, with error bars at each time point.*
1 (Image 6)
A line graph comparing the proportion of subjects with relapse or treatment failure (%) over time (days after randomization) for Lisdexamfetamine dimesylate capsules versus placebo. The graph shows a lower relapse/treatment failure rate for Lisdexamfetamine dimesylate capsules compared to placebo across the 50-day period.*
1 (Image 7)
A line graph comparing LS Mean (SE) PERMP Total Scores over time post-dose (hours) between placebo and Lisdexamfetamine Dimesylate capsules. The graph shows scores on the y-axis ranging approximately from 250 to 330, with time points from -0.5 to 14 hours on the x-axis. Lisdexamfetamine Dimesylate scores increase sharply and plateau above placebo scores throughout the period.*
1 (Image 8)
A Kaplan-Meier plot showing the proportion of subjects with relapse or treatment failure over time (days after randomization) comparing Lisdexamfetamine Dimesylate Capsules to placebo. The graph illustrates a lower proportion of relapse/treatment failure in subjects taking Lisdexamfetamine Dimesylate versus placebo during the study period up to 35 days.*
1 (Image 9)
A line chart comparing the proportion of subjects with relapse over time between Lisdexamfetamine Dimesylate Capsules and Placebo groups. The x-axis shows days after randomization from 0 to 209, and the y-axis shows the proportion of subjects with relapse as a percentage from 0 to 100%. The solid line represents Lisdexamfetamine Dimesylate Capsules, showing near zero relapse rate, while the dashed line for Placebo shows an increasing relapse rate up to about 35%. The chart also includes a table below showing the number of subjects at risk over time for both groups.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
